The Mumbai-based drugmaker at that time had stated that it intends to acquire Avenue Therapeutics, a Fortress Biotech company, in two stages.
Drug major Cipla on Wednesday said its auxiliary InvaGen Pharmaceuticals will keep on holding shares in US-based Avenue Therapeutics notwithstanding end of the stock buy and consolidation agreement they inked in 2018. In November 2018, Cipla had reported that InvaGen Pharmaceuticals Inc has gone into definitive agreements to obtain US-based speciality business firm Avenue Therapeutics for up to USD 215 million.
Suggestion For You:
In November last year, the drug maker, however, announced that InvaGen has received a notice from Avenue for termination of the acquisition deal they inked in 2018.
The stock purchase and merger agreement (SPMA) entered between InvaGen and Avenue has been terminated with effect from November 1, 2021, Cipla said in a regulatory filing.
“However, the stockholders agreement November 12, 2018 between InvaGen, Avenue and other stockholders remains in force; and InvaGen will continue to hold shares in Avenue,” it added.
Avenue Therapeutics is focused on development and commercialisation of intravenous (IV), Tramadol, a painkiller.
For Latest News Follow us on Google News
- Show all
- Trending News
- Popular By week